Get the Stockscreener App
12.47
0.64%
-0.095
Aardvark Therapeutics Inc stock is traded at $12.47, with a volume of 7,674.
It is down -0.64% in the last 24 hours and down -10.27% over the past month.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
See More
Previous Close:
$12.57
Open:
$12.58
24h Volume:
7,674
Relative Volume:
0.15
Market Cap:
$273.37M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.00%
1M Performance:
-10.27%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$12.58
$13.24
1-Week Range:
$11.50
$13.63
52-Week Range:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Name
Aardvark Therapeutics Inc
Sector
Industry
Phone
(858) 225-7696
Address
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
12.60 | 272.19M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.43 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.36 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.06 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.26 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.09 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Initiated | BofA Securities | Buy |
| Mar-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-10-25 | Initiated | Morgan Stanley | Overweight |
| Mar-10-25 | Initiated | RBC Capital Mkts | Outperform |
Aardvark Therapeutics Inc Stock (AARD) Latest News
Is Aardvark Therapeutics Inc. meeting your algorithmic filter criteriaEquity Performance Forecast Based on AI Models - Newser
Technical signs of recovery in Aardvark Therapeutics Inc.Free Accurate Technical Trend Reversal Picks - Newser
Moving Average Trends for Aardvark Therapeutics Inc. Stock: What They IndicateFree Community Verified Stock Suggestions - Newser
Can machine learning forecast Aardvark Therapeutics Inc. recoveryFree Proven Entry Plan With Low Risk Trade - Newser
Why Aardvark Therapeutics Inc. stock is on top investor watchlistsFree Triple Digit Return Stock Predictions - Newser
Published on: 2025-08-05 19:48:37 - Newser
News impact scoring models applied to Aardvark Therapeutics Inc.Free Fundamental + Technical Hybrid Stock Tips - Newser
Aardvark Therapeutics, Inc.’s (NASDAQ:AARD) Lock-Up Period Set To Expire on August 12th - Defense World
Combining price and volume data for Aardvark Therapeutics Inc.Free Capital Preserving Trade Plan Templates - Newser
Volume spikes in Aardvark Therapeutics Inc. stock – what they meanFree Quick Gain Stock Watch With Indicators - Newser
Why Aardvark Therapeutics Inc. stock attracts strong analyst attentionShort Term Gain Strategy with AI Logic - Newser
What analysts say about Aardvark Therapeutics Inc. stockBuild wealth steadily with smart trading - Jammu Links News
Evaluating Aardvark Therapeutics Inc. with trendline analysisWealth Accumulation Outlook for Safe Investors - Newser
Why is Aardvark Therapeutics Inc. stock attracting strong analyst attentionUnlock daily market insights for better decisions - Jammu Links News
Applying big data sentiment scoring on Aardvark Therapeutics Inc.Risk-Managed Trade Alerts for Consistency - newser.com
What are the latest earnings results for Aardvark Therapeutics Inc.Consistent double returns - Jammu Links News
Risk vs reward if holding onto Aardvark Therapeutics Inc.High Conviction Stock Long-Term Summary - newser.com
Is Aardvark Therapeutics Inc. a good long term investmentInvest smarter with data-backed insights - Jammu Links News
How does Aardvark Therapeutics Inc. compare to its industry peersBuild a portfolio that outperforms the market - Jammu Links News
How does Aardvark Therapeutics Inc. generate profit in a changing economyDiscover investment plans that deliver results - Jammu Links News
What makes Aardvark Therapeutics Inc. stock price move sharplyAchieve breakthrough financial results - Jammu Links News
What are analysts’ price targets for Aardvark Therapeutics Inc. in the next 12 monthsUnmatched profit potential - Jammu Links News
Published on: 2025-08-03 04:04:58 - Jammu Links News
Reversal indicators forming on Aardvark Therapeutics Inc. stockSmart Stock Forecast Using AI Algorithms - Newser
Strategies to average down on Aardvark Therapeutics Inc.Free Risk-Adjusted Picks With Exit Strategy - Newser
Earnings visualization tools for Aardvark Therapeutics Inc.Daily Pick Forecast with Entry Zones - Newser
What’s next for Aardvark Therapeutics Inc. stock priceEarnings Impact and Stock Reaction Analysis - Newser
Sector ETF performance correlation with Aardvark Therapeutics Inc.Breakout Entry Signal Confirmation Tool Used - metal.it
Published on: 2025-07-30 23:36:06 - Newser
Aardvark Therapeutics Inc Stock (AARD) Financials Data
There is no financial data for Aardvark Therapeutics Inc (AARD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Aardvark Therapeutics Inc Stock (AARD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lee Tien-Li | Chief Executive Officer |
Feb 14 '25 |
Buy |
16.00 |
16,542 |
264,672 |
1,496,175 |
| Sun Nelson | Chief Financial Officer |
Feb 14 '25 |
Buy |
16.00 |
10,000 |
160,000 |
99,484 |
| Cormorant Asset Management, LP | Former 10% Owner |
Feb 14 '25 |
Buy |
16.00 |
187,500 |
3,000,000 |
987,689 |
0.36%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):